0001493152-24-006906.txt : 20240216 0001493152-24-006906.hdr.sgml : 20240216 20240215184710 ACCESSION NUMBER: 0001493152-24-006906 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240215 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAVmed Inc. CENTRAL INDEX KEY: 0001624326 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 471214177 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37685 FILM NUMBER: 24645310 BUSINESS ADDRESS: STREET 1: 360 MADISON AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (212) 949-4319 MAIL ADDRESS: STREET 1: 360 MADISON AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PAXmed Inc. DATE OF NAME CHANGE: 20141105 8-K 1 form8-k.htm
false 0001624326 0001624326 2024-02-15 2024-02-15 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2024-02-15 2024-02-15 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2024-02-15 2024-02-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 15, 2024

 

PAVMED INC.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-37685   47-1214177

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

360 Madison Avenue, 25th Floor, New York, New York   10017
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (917) 813-1828

 

N/A

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   PAVM   The Nasdaq Stock Market LLC
Series Z Warrants to Purchase Common Stock   PAVMZ   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

See the information under Item 8.01, which is incorporated under this Item by reference.

 

Item 3.03. Material Modification to Rights of Security Holders.

 

See the information under Item 8.01, which is incorporated under this Item by reference.

 

Item 8.01. Other Events.

 

On February 15, 2024, PAVmed Inc. (the “Company”) distributed to its common and preferred stockholders 3,331,747 shares of common stock of Lucid Diagnostics Inc., the Company’s majority owned subsidiary (“Lucid Diagnostics”), through a special pro rata dividend. The shares being distributed by the Company represent approximately 6.9% of Lucid Diagnostics’ common stock outstanding. After the distribution, the Company will continue to own approximately 65.2% of Lucid Diagnostics’ common stock.

 

Based on the number of shares of the Company’s stock outstanding as of January 15, 2024, the record date, each Company stockholder was entitled to receive 0.37709668 of a share of Lucid Diagnostics’ common stock for each share of the Company’s common stock held (in the case of the Company’s preferred stock, as if such preferred stock had been converted into common stock) as of 5:00 p.m. Eastern Time on the record date. The holder of the Company’s senior convertible notes waived its right to participate in the distribution. The Company did not distribute fractional shares of Lucid Diagnostics’ common stock. Instead, the Company rounded each Company stockholders’ entitlement to Lucid Diagnostics shares to the nearest whole number of shares.

 

In connection with the distribution, the exercise price of the Company’s outstanding Series Z Redeemable Warrants (the “Series Z Warrants”) is being adjusted in accordance with the terms of the warrants. In accordance with Section 4.3 of the Amended and Restated Series Z Warrant Agreement, dated as of June 8, 2018, by and between the Company and the warrant agent, the exercise price of the Series Z Warrants is being decreased by the fair market value of the special dividend, or $0.52 per share, from $24.00 per share to $23.48 per share.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 15, 2024

 

  PAVMED INC.
     
  By: /s/ Dennis M. McGrath
    Dennis M. McGrath
    President and Chief Financial Officer

 

 

 

 EX-101.SCH 2 pavm-20240215.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 pavm-20240215_def.xml XBRL DEFINITION FILE EX-101.LAB 4 pavm-20240215_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, Par Value $0.001 Per Share Series Z Warrants to Purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 pavm-20240215_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 15, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 15, 2024
Entity File Number 001-37685
Entity Registrant Name PAVMED INC.
Entity Central Index Key 0001624326
Entity Tax Identification Number 47-1214177
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 360 Madison Avenue
Entity Address, Address Line Two 25th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10017
City Area Code (917)
Local Phone Number 813-1828
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, Par Value $0.001 Per Share  
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol PAVM
Security Exchange Name NASDAQ
Series Z Warrants to Purchase Common Stock  
Title of 12(b) Security Series Z Warrants to Purchase Common Stock
Trading Symbol PAVMZ
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm pavm-20240215.xsd pavm-20240215_def.xml pavm-20240215_lab.xml pavm-20240215_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20240215", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "pavm-20240215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "pavm-20240215_def.xml" ] }, "labelLink": { "local": [ "pavm-20240215_lab.xml" ] }, "presentationLink": { "local": [ "pavm-20240215_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://pavmed.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://pavmed.com/role/Cover" ], "auth_ref": [] }, "PAVM_CommonStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240215", "localname": "CommonStockParValue0.001PerShareMember", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value $0.001 Per Share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "PAVM_SeriesZWarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240215", "localname": "SeriesZWarrantsToPurchaseCommonStockMember", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Series Z Warrants to Purchase Common Stock" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-006906-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-006906-xbrl.zip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end XML 16 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001624326 2024-02-15 2024-02-15 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2024-02-15 2024-02-15 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2024-02-15 2024-02-15 iso4217:USD shares iso4217:USD shares false 0001624326 8-K 2024-02-15 PAVMED INC. DE 001-37685 47-1214177 360 Madison Avenue 25th Floor New York NY 10017 (917) 813-1828 false false false false Common Stock, Par Value $0.001 Per Share PAVM NASDAQ Series Z Warrants to Purchase Common Stock PAVMZ NASDAQ false